Observational Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. May 14, 2023; 29(18): 2875-2887
Published online May 14, 2023. doi: 10.3748/wjg.v29.i18.2875
Figure 1
Figure 1 Abdominal computed tomography images at the level of the third lumbar vertebrae were used to measure the transversal psoas muscle thickness and psoas muscle attenuation in a 45-year-old man without sarcopenia and myosteatosis, and a 51-year-old man with sarcopenia and myosteatosis. A: The axial computed tomography (CT) scan image of a 45-year-old cirrhotic patient (height: 1.74 m, weight: 74 kg) who developed variceal rebleeding; B and C: The patient had normal transversal psoas muscle thickness (TPMT) and psoas muscle attenuation (PMA) levels: 12.3 mm/m (21.4 mm/1.74 m) and 46.4 HU, respectively; D-F: The axial CT scan image of a 51-year-old cirrhotic patient (height: 1.72 m, weight: 55 kg) who developed refractory ascites (D), and had low TPMT and PMA (6.5 mm/m [11.2 mm/1.72 m] and 34.5 HU) (E and F). TPMT: Transversal psoas muscle thickness.
Figure 2
Figure 2 Receiver operating characteristic curves for the probability of transversal psoas muscle thickness, psoas muscle attenuation, and neutrophil-lymphocyte ratio in predicting overt hepatic encephalopathy. TPMT: Transversal psoas muscle thickness; PMA: Psoas muscle attenuation; NLR: Neutrophil-lymphocyte ratio.
Figure 3
Figure 3 Kaplan-Meier curves for the cumulative incidence of post-transjugular intrahepatic portosystemic shunt overt hepatic encephalopathy. A: For all patients; B: For patients with and without myosteatosis; C: For patients with and without sarcopenia; D: For patients with coexisting sarcopenia and myosteatosis. HE: Hepatic encephalopathy.
Figure 4
Figure 4 Kaplan-Meier curves for the cumulative survival rate of post-transjugular intrahepatic portosystemic shunt. A: For all patients; B: For patients with and without hepatic encephalopathy; C: For patients with and without myosteatosis; D: For patients with and without sarcopenia; E: For patients with coexisting sarcopenia and myosteatosis. HE: Hepatic encephalopathy.